UCB has been granted a patent for cyclic polypeptide compounds that can bind to human PCSK9, potentially reducing LDL cholesterol levels. The patent also covers methods of administering these compounds to inhibit PCSK9-LDLR interaction. GlobalData’s report on UCB gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on UCB, Human telomerase RT biomarker was a key innovation area identified from patents. UCB's grant share as of May 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US12012468B2) discloses a cyclic peptide formula aimed at reducing low-density lipoprotein (LDL) cholesterol levels in individuals with hypercholesterolemia. The cyclic peptide, as outlined in the claims, inhibits the interaction between human PCSK9 and the epidermal growth factor-like repeat A (EGF-A) domain of human LDLR, offering a potential therapeutic solution for managing cholesterol levels.
Moreover, the patent claims cover methods for treating hypercholesterolemia and inhibiting PCSK9 activity in both subjects and cells by administering the cyclic peptide. The patent also extends to inhibiting the interaction between PCSK9 and the EGF-A domain of LDLR, showcasing the versatility of the cyclic peptide in addressing various conditions associated with high cholesterol levels. The methods of administration include oral, intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, and intravitreal routes, providing flexibility in delivering the therapeutic benefits of the cyclic peptide to those in need.
To know more about GlobalData’s detailed insights on UCB, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
